Shares of Gilead Sciences Inc. (NASDAQ:GILD) have received a consensus recommendation of “Buy” from the thirty-one ratings firms that are presently covering the company. Ten investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $97.37.

GILD has been the subject of several research reports. Credit Suisse Group AG reduced their price objective on Gilead Sciences from $115.00 to $95.00 and set an “outperform” rating for the company in a report on Wednesday, September 14th. Jefferies Group reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Thursday, August 25th. Piper Jaffray Cos. reaffirmed an “overweight” rating on shares of Gilead Sciences in a report on Tuesday, August 16th. RBC Capital Markets reduced their price objective on Gilead Sciences from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Wednesday, November 2nd. Finally, S&P Equity Research reaffirmed a “strong-buy” rating on shares of Gilead Sciences in a report on Wednesday, July 27th.

Gilead Sciences (NASDAQ:GILD) opened at 74.62 on Friday. The firm’s 50-day moving average is $74.94 and its 200 day moving average is $80.59. Gilead Sciences has a 1-year low of $71.39 and a 1-year high of $108.63. The company has a market cap of $98.31 billion, a PE ratio of 6.90 and a beta of 1.25.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 EPS for the quarter, missing the consensus estimate of $2.87 by $0.12. The business earned $7.40 billion during the quarter, compared to analyst estimates of $7.47 billion. Gilead Sciences had a net margin of 47.74% and a return on equity of 100.57%. The firm’s quarterly revenue was down 9.6% compared to the same quarter last year. During the same period in the prior year, the business earned $3.22 earnings per share. Analysts predict that Gilead Sciences will post $11.47 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 29th. Investors of record on Thursday, December 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date is Tuesday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 17.44%.

In other Gilead Sciences news, insider John C. Martin sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $77.63, for a total value of $7,763,000.00. Following the completion of the sale, the insider now directly owns 3,231,096 shares in the company, valued at $250,829,982.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kevin E. Lofton sold 3,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 24th. The stock was sold at an average price of $81.97, for a total value of $286,895.00. The disclosure for this sale can be found here. 1.40% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in GILD. Van Hulzen Asset Management LLC increased its stake in Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 100 shares during the period. Penserra Capital Management LLC increased its stake in Gilead Sciences by 148.3% in the third quarter. Penserra Capital Management LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 774 shares during the period. Gemmer Asset Management LLC increased its stake in Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 175 shares during the period. Joel Isaacson & Co. LLC increased its stake in Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 226 shares during the period. Finally, Roble Belko & Company Inc increased its stake in Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,035 shares during the period. Hedge funds and other institutional investors own 76.90% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.